Kanada - englanti - Health Canada

aa pharma inc - levodopa; carbidopa - tablet (extended-release) - 100mg; 25mg - levodopa 100mg; carbidopa 25mg - dopamine precursors

Kanada - englanti - Health Canada

pro doc limitee - carbidopa; levodopa - tablet - 25mg; 100mg - carbidopa 25mg; levodopa 100mg - dopamine precursors

Kanada - englanti - Health Canada

mint pharmaceuticals inc - levodopa; carbidopa - tablet - 100mg; 10mg - levodopa 100mg; carbidopa 10mg - dopamine precursors

Kanada - englanti - Health Canada

mint pharmaceuticals inc - levodopa; carbidopa - tablet - 100mg; 25mg - levodopa 100mg; carbidopa 25mg - dopamine precursors

Kanada - englanti - Health Canada

mint pharmaceuticals inc - levodopa; carbidopa - tablet - 250mg; 25mg - levodopa 250mg; carbidopa 25mg - dopamine precursors

Yhdysvallat - englanti - NLM (National Library of Medicine)

caraco pharmaceutical laboratories, ltd. - ticlopidine hydrochloride (unii: a1l4914fmf) (ticlopidine - unii:om90zuw7m1) - ticlopidine hydrochloride 250 mg - indications and usage: ticlopidine hydrochloride tablets usp are indicated: - to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (ttp), neutropenia/agranulocytosis and aplastic anemia (see boxed warning and warnings ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. - as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see clinical trials ). contraindications: the use of ticlopidine is contraindicated in the following conditions: - hypersensitivity to the drug - presence of hematopoietic disorders such as neutropenia and thrombocytopenia or a past history of either ttp or aplastic an

Yhdysvallat - englanti - NLM (National Library of Medicine)

eon labs, inc. - ticlopidine hydrochloride (unii: a1l4914fmf) (ticlopidine - unii:om90zuw7m1) - ticlopidine hydrochloride 250 mg - ticlopidine hydrochloride tablets are indicated: - to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (ttp), neutropenia/agranulocytosis and aplastic anemia (see box warning  and warnings ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. - as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see clinical trials ). the use of ticlopidine is contraindicated in the following conditions: - hypersensitivity to the drug - presence of hematopoietic disorders such as neutropenia and thrombocytopenia or a past history of either ttp or aplastic anemia - presence of a hemostatic disorder or active

Yhdysvallat - englanti - NLM (National Library of Medicine)

carilion materials management - ticlopidine hydrochloride (unii: a1l4914fmf) (ticlopidine - unii:om90zuw7m1) - ticlopidine hydrochloride 250 mg - ticlopidine hydrochloride tablets usp are indicated: - to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (ttp), neutropenia/agranulocytosis and aplastic anemia (see and ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. boxed warning warnings - as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see ). clinical trials the use of ticlopidine is contraindicated in the following conditions: - hypersensitivity to the drug - presence of hematopoietic disorders such as neutropenia and thrombocytopenia or a past history of either

Kanada - englanti - Health Canada

hoffmann-la roche limited - levodopa; benserazide (benserazide hydrochloride) - capsule - 100mg; 25mg - levodopa 100mg; benserazide (benserazide hydrochloride) 25mg - dopamine precursors

Kanada - englanti - Health Canada

hoffmann-la roche limited - levodopa; benserazide (benserazide hydrochloride) - capsule - 200mg; 50mg - levodopa 200mg; benserazide (benserazide hydrochloride) 50mg - dopamine precursors